With the shares trading at around 235p, below the proposal, and interim results pushed back to 30 September, the coming weeks will decide whether a year-long strategic review ends in an agreed takeover or a return to standalone life.
The question is whether that shift from loss to profit is durable. The board argued in March that its fundamentals were "not yet fully reflected" in its market value, yet a single customer supplied almost half of first-half revenue.
Integrated Diagnostics Holdings Plc (LSE:IDHC) has just come through one of the more unusualTakeoverbattles on theLondon Stock Exchangethis year. Its own chief executive, Dr Hend El Sherbini, through family vehicle Hena Holdings, launched a mandatory cash offer at US$0.50 per share that the independent …
Venture Life Group Plc (LSE:VLG) has spent the past fourteen months quietly reinventing itself. The consumer self-care company sold its ItalianManufacturingarm for anEnterprise valueof €62m in July 2025, offloaded its oral care brands in December, and on 3 June 2026 announced its first move …
Diaceutics Plc (LSE:DXRX) has spent the past year converting one-off pharmaceutical consulting work into subscription-style contracts, and the numbers now show it. On 29 July 2026 the Belfast-founded precision medicine data company reported annual recurring revenue of £28.8m at 30 June, up 75% on …
Arecor Therapeutics PLC (LSE:AREC) has spent 2026 turning a drug-delivery technologyBusinessinto a focused diabetes and obesity play, and the next six months will show whether that bet pays off. The Cambridge-based biotech aims to take AT278, an ultra-concentrated, ultra-rapid-acting insulin, into Phase 2 in …
ValiRx PLC (LSE:VAL) has spent eighteen months shrinking and restructuring itself into something quite different from the clinical-stage drug developer of a few years ago. The question now is whether the new model, in which the London-listed group evaluates university science in its own …
Oxford Biomedica has suddenly become one of the more closely watched healthcare stocks in London because the company's share price is being caught between two very different narratives.
Applied Nutrition PLC has emerged as one of the fastest-growing UK-listed consumer health and sports-nutrition businesses, building a portfolio of products across sports nutrition, health, wellness and functional supplements.
EDX Medical Group became one of the notable decliners on 2 September, withLSE:EDX down 10.00%.